Study Summary
This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression
Want to learn more about this trial?
Request More InfoInterventions
Claudin 18.2 CAR-TBIOLOGICAL
treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Changhai Hospital | Shanghai | Shanghai Municipality | China |